HC Wainwright & Co. Maintains Buy on Palvella Therapeutics, Raises Price Target to $200

Benzinga · 1d ago
HC Wainwright & Co. analyst Andrew S. Fein maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy and raises the price target from $190 to $200.